
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
In a continuing series from Dermatology Times, a panel of pediatric masters discusses treatment options for specific and unusual cases. This third case is that of a 15-month-old male brought in by his mother for management of perianal warts. What are the various treatment options for the child?